Zhu Yi-Pan, Sun Jing, Cao Xin-Yu, Ding Xin-Yu, Wang Yu-Ying, Han Qiu-Ju, Wang Jing-Ying, Li Lu-Yuan, Zhang Zhi-Song
State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, The Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin, 300350, China.
School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
Acta Pharmacol Sin. 2025 Sep 19. doi: 10.1038/s41401-025-01663-y.
Myeloid-derived suppressor cells (MDSCs) are a category of immature myeloid cells that have an important function in suppressing immune responses in a variety of pathological settings. Thus, MDSCs are the subject of intensive studies regarding their recruitment, expulsion, deactivation, and maturation promotion. Tumor necrosis factor superfamily member 15 (TNFSF15) is produced largely by vascular endothelial cells in mature blood vessels with expression also observed in tumor-associated macrophages (TAMs) and dendritic cells (DCs) within the tumor stroma. In addition to inhibiting the proliferation of vascular endothelial cells and the differentiation of bone marrow-derived endothelial cell progenitors, TNFSF15 is able to promote the maturation of DC, as well as to modulate the polarization of naive M2-macrophages into M1-macrophages capable of eliminating cancer cells, and activate T-cell. In this study, we investigated whether a recombinant TNFSF15 results in a substantial reduction of MDSC accumulation in Lewis lung cancer (LLC) tumor-bearing mice. LLC allograft model mice were administered recombinant TNFSF15 (5 mg·kg·d, i.p.) for 7 consecutive days. The tumor, bone marrow and spleen were retrieved on Day 8 and analyzed using flow cytometry or immunofluorescence staining. We showed that TNFSF15 treatment significantly inhibited the tumor growth, and caused a substantial reduction of MDSC accumulation in the tumors. The proportions of MDSC in the bone marrows and the spleens were also reduced. The diminished MDSC was mainly the monocyte-like MDSC (M-MDSC) subtype. Additionally, the reduction in M-MDSC population was accompanied by an increase of the proportions of macrophages and DCs in the tumors. We demonstrated that TNFSF15 promoted M-MDSC differentiation by activating the JAK1/STAT3 signaling pathway. Moreover, the treatment gave rise to a markedly escalated accumulation of cytotoxic T cells in the tumors, attributing to tumor growth inhibition. Our results support the view that TNFSF15-driven differentiation of M-MDSC into DCs and macrophages, and the subsequent activation of T cells, may contribute partially to reinstitution of immunity in the tumor microenvironment.
髓源性抑制细胞(MDSCs)是一类未成熟的髓样细胞,在多种病理情况下对抑制免疫反应具有重要作用。因此,MDSCs成为了关于其募集、清除、失活和促进成熟等方面深入研究的对象。肿瘤坏死因子超家族成员15(TNFSF15)主要由成熟血管中的血管内皮细胞产生,在肿瘤相关巨噬细胞(TAM)和肿瘤基质中的树突状细胞(DC)中也有表达。除了抑制血管内皮细胞的增殖和骨髓来源的内皮细胞祖细胞的分化外,TNFSF15还能够促进DC的成熟,以及调节幼稚M2巨噬细胞向能够消除癌细胞的M1巨噬细胞的极化,并激活T细胞。在本研究中,我们调查了重组TNFSF15是否能显著减少荷Lewis肺癌(LLC)小鼠体内MDSC的积累。将重组TNFSF15(5mg·kg·d,腹腔注射)连续7天给予LLC同种异体移植模型小鼠。在第8天取出肿瘤、骨髓和脾脏,使用流式细胞术或免疫荧光染色进行分析。我们发现TNFSF15治疗显著抑制了肿瘤生长,并导致肿瘤中MDSC的积累大幅减少。骨髓和脾脏中MDSC的比例也降低了。减少的MDSC主要是单核细胞样MDSC(M-MDSC)亚型。此外,M-MDSC数量的减少伴随着肿瘤中巨噬细胞和DC比例的增加。我们证明TNFSF15通过激活JAK1/STAT3信号通路促进M-MDSC分化。此外,该治疗导致肿瘤中细胞毒性T细胞的积累明显增加,这归因于肿瘤生长受到抑制。我们的结果支持这样一种观点,即TNFSF15驱动M-MDSC分化为DC和巨噬细胞,以及随后T细胞的激活,可能部分有助于恢复肿瘤微环境中的免疫功能。